2C-iBu

2,5-Dimethoxy-4-isobutylphenethylamine (2C-iBu or 2C-IB), also known by its developmental code name ELE-02, is a serotonin 5-HT_2A receptor agonist, serotonergic psychedelic, and anti-inflammatory drug which is under development for the treatment of inflammation. It is a member of the phenethylamine and 2C families of compounds. The drug is being developed as a topical eye drop for treatment of inflammatory eye conditions. There is also interest in 2C-iBu and related drugs for treatment of systemic inflammation and neuroinflammation.

2C-iBu was not assessed or discovered by Alexander Shulgin and was not described in PiHKAL (Phenethylamines I Have Known and Loved) (1991). However, he did include 2C-iBu (as "2C-IB") as a DOM analogue in a table in The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (2011). In addition, he stated in a footnote that a 5 mg oral dose of 2C-iBu produces threshold activity and has a long duration of about 20 hours. The cited source for these observations, however, was only a 2006 personal communication with "M. Mueller."

2C-iBu was subsequently more thoroughly characterized by Charles D. Nichols and colleagues at Louisiana State University School of Medicine as a novel anti-inflammatory drug in the late 2010s. Eleusis has licensed 2C-iBu intellectual property from LSU and the drug has reached the preclinical research stage of development, but no recent development has been reported as of October 2023.